Skip to main content
Top
Published in: Respiratory Research 1/2020

01-12-2020 | Expectoration | Research

Different expression levels of interleukin-35 in asthma phenotypes

Authors: Wei Li, Ruihan Gao, Tong Xin, Peng Gao

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

Interleukin (IL)-35 is a newly discovered inhibitory cytokine which is produced by regulatory B and T lymphocytes and belongs to the IL-12 family. It plays a suppressive role in human inflammatory diseases; however, its role in asthma phenotypes is unclear. Our study focuses on the sputum IL-35 level in patients and investigates different airway inflammation capacities of sputum IL-35 in patients with different asthma phenotypes.

Objective

We aimed to determine the sputum IL-35 levels in asthmatic patients with clinical remission phenotypes and control subjects and to investigate possible correlations among lung function, age, sex, fractional exhaled nitric oxide (FeNO), and smoking history in these phenotypes.

Methods

Sputum samples were collected from patients with clinical asthma remission (n = 89, 37 males, age 52.24 ± 13.32 years) and a healthy control group (n = 19, 9 males, age 44.58 ± 16.3 years). All subjects underwent sputum induction. Induced sputum was assessed for inflammatory cell count, and sputum levels of IL-35 and other cytokines were measured by ELISA and Cytometric Bead Array, respectively.

Results

Sputum IL-35 (median (q1, q3)) levels showed no significant difference between asthma patients (4.89 ng/mL (2.97, 22.75)) and healthy controls (6.01 ng/mL (4.09, 30.47)). However, the sputum IL-35 level was significantly reduced in patients with eosinophilic asthma (EA) (3.95 ng/mL (2.80, 11.00)) compared to patients with neutrophilic asthma (NA) (40.59 ng/mL (20.59, 65.06), p = 0.002), paucigranulocytic asthma (PA) (6.25 ng/mL (3.10, 24.60), p = 0.012), and mixed granulocytic asthma (MA) (22.54 ng/mL (2.58, 52.45), p = 0.026). IL-35 levels in sputum showed a positive correlation with sputum neutrophil cells and a negative correlation with FeNO, FEV1% predicted, and FVC predicted. Furthermore, sputum IL-35 had a significant positive association with Th1-related factors and a negative correlation with Th2-related factors.

Conclusions

Sputum IL-35 is likely involved in different pathophysiological mechanisms of NA and EA and exerts different effects in asthma phenotypes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mortality GBD. Causes of death C: global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–544.CrossRef Mortality GBD. Causes of death C: global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–544.CrossRef
2.
go back to reference Gao P, Gibson PG, Baines KJ, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, et al. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1beta. Respir Res. 2015;16:5.PubMedPubMedCentralCrossRef Gao P, Gibson PG, Baines KJ, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, et al. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1beta. Respir Res. 2015;16:5.PubMedPubMedCentralCrossRef
4.
go back to reference Perlikos F, Hillas G, Loukides S. Phenotyping and Endotyping asthma based on biomarkers. Curr Top Med Chem. 2016;16:1582–6.PubMedCrossRef Perlikos F, Hillas G, Loukides S. Phenotyping and Endotyping asthma based on biomarkers. Curr Top Med Chem. 2016;16:1582–6.PubMedCrossRef
5.
go back to reference Bruijnzeel PL, Uddin M, Koenderman L. Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype? J Leukoc Biol. 2015;98:549–56.PubMedCrossRef Bruijnzeel PL, Uddin M, Koenderman L. Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype? J Leukoc Biol. 2015;98:549–56.PubMedCrossRef
6.
go back to reference Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009;3:198–206.PubMedCrossRef Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J. 2009;3:198–206.PubMedCrossRef
7.
go back to reference Sousa AR, Marshall RP, Warnock LC, Bolton S, Hastie A, Symon F, Hargadon B, Marshall H, Richardson M, Brightling CE, et al. Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation. Clin Exp Allergy. 2017;47:890–9.PubMedCrossRef Sousa AR, Marshall RP, Warnock LC, Bolton S, Hastie A, Symon F, Hargadon B, Marshall H, Richardson M, Brightling CE, et al. Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation. Clin Exp Allergy. 2017;47:890–9.PubMedCrossRef
8.
go back to reference Pavord ID, Afzalnia S, Menzies-Gow A, Heaney LG. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy. 2017;47:148–60.PubMedCrossRef Pavord ID, Afzalnia S, Menzies-Gow A, Heaney LG. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy. 2017;47:148–60.PubMedCrossRef
9.
go back to reference Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S2–6.PubMedCrossRef Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S2–6.PubMedCrossRef
10.
11.
go back to reference Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–46.PubMedCrossRef Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–46.PubMedCrossRef
12.
go back to reference Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012;13:290–9.PubMedPubMedCentralCrossRef Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, Satoskar AR, Garcia KC, Hunter CA, Drake CG, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012;13:290–9.PubMedPubMedCentralCrossRef
13.
go back to reference Tong H, Miyazaki Y, Yamazaki M, Hara H, Waldmann H, Hori S, Yoshida H. Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice. Immunol Lett. 2010;128:108–15.PubMedCrossRef Tong H, Miyazaki Y, Yamazaki M, Hara H, Waldmann H, Hori S, Yoshida H. Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice. Immunol Lett. 2010;128:108–15.PubMedCrossRef
14.
go back to reference Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J, Bai XF. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol. 2012;188:3099–106.PubMedCrossRef Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J, Bai XF. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol. 2012;188:3099–106.PubMedCrossRef
15.
go back to reference Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, Lee BW, Chua KY. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol. 2011;187:462–71.PubMedCrossRef Huang CH, Loo EX, Kuo IC, Soh GH, Goh DL, Lee BW, Chua KY. Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35. J Immunol. 2011;187:462–71.PubMedCrossRef
16.
go back to reference Wong CK, Leung TF, Chu IM, Dong J, Lam YY, Lam CW. Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma. Inflammation. 2015;38:348–60.PubMedCrossRef Wong CK, Leung TF, Chu IM, Dong J, Lam YY, Lam CW. Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma. Inflammation. 2015;38:348–60.PubMedCrossRef
17.
go back to reference Wang W, Li P, Yang J. Decreased circulating Interleukin-35 levels are related to Interleukin-4-producing CD8+ T cells in patients with allergic asthma. Iran J Allergy Asthma Immunol. 2015;14:379–85.PubMedCrossRef Wang W, Li P, Yang J. Decreased circulating Interleukin-35 levels are related to Interleukin-4-producing CD8+ T cells in patients with allergic asthma. Iran J Allergy Asthma Immunol. 2015;14:379–85.PubMedCrossRef
18.
go back to reference Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987;136:225–44. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987;136:225–44.
19.
go back to reference Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AW, Clancy RL. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998;158:36–41.PubMedCrossRef Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AW, Clancy RL. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am J Respir Crit Care Med. 1998;158:36–41.PubMedCrossRef
20.
go back to reference Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Systemic upregulation of neutrophil alpha-defensins and serine proteases in neutrophilic asthma. Thorax. 2011;66:942–7.PubMedCrossRef Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Systemic upregulation of neutrophil alpha-defensins and serine proteases in neutrophilic asthma. Thorax. 2011;66:942–7.PubMedCrossRef
21.
go back to reference Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–7.PubMedCrossRef Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902–7.PubMedCrossRef
22.
go back to reference Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.PubMedCrossRef Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.PubMedCrossRef
23.
go back to reference Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.PubMedPubMedCentralCrossRef Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83.PubMedPubMedCentralCrossRef
26.
go back to reference Hoppe S, Keel MJ. Pedicle screw augmentation in osteoporotic spine: indications, limitations and technical aspects. Eur J Trauma Emerg Surg. 2017;43:3–8.PubMedCrossRef Hoppe S, Keel MJ. Pedicle screw augmentation in osteoporotic spine: indications, limitations and technical aspects. Eur J Trauma Emerg Surg. 2017;43:3–8.PubMedCrossRef
27.
go back to reference Mansour AI, Abd Almonaem ER, Behairy OG, Gouda TM. Predictive value of IL-35 and IL-17 in diagnosis of childhood asthma. Scand J Clin Lab Invest. 2017;77:373–8.PubMedCrossRef Mansour AI, Abd Almonaem ER, Behairy OG, Gouda TM. Predictive value of IL-35 and IL-17 in diagnosis of childhood asthma. Scand J Clin Lab Invest. 2017;77:373–8.PubMedCrossRef
28.
go back to reference Kanai K, Park AM, Yoshida H, Tsunoda I, Yoshie O. IL-35 suppresses lipopolysaccharide-induced airway eosinophilia in EBI3-deficient mice. J Immunol. 2017;198:119–27.PubMedCrossRef Kanai K, Park AM, Yoshida H, Tsunoda I, Yoshie O. IL-35 suppresses lipopolysaccharide-induced airway eosinophilia in EBI3-deficient mice. J Immunol. 2017;198:119–27.PubMedCrossRef
29.
go back to reference Zou JM, Qin J, Li YC, Wang Y, Li D, Shu Y, Luo C, Wang SS, Chi G, Guo F, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget. 2017;8:33501–14.PubMedPubMedCentral Zou JM, Qin J, Li YC, Wang Y, Li D, Shu Y, Luo C, Wang SS, Chi G, Guo F, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget. 2017;8:33501–14.PubMedPubMedCentral
30.
go back to reference Filkova M, Vernerova Z, Hulejova H, Prajzlerova K, Veigl D, Pavelka K, Vencovsky J, Senolt L. Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine. 2015;73:36–43.PubMedCrossRef Filkova M, Vernerova Z, Hulejova H, Prajzlerova K, Veigl D, Pavelka K, Vencovsky J, Senolt L. Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis. Cytokine. 2015;73:36–43.PubMedCrossRef
31.
go back to reference Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, Lutomski D, Boissier MC, Bessis N. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 2014;69:87–93.PubMedCrossRef Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, Lutomski D, Boissier MC, Bessis N. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 2014;69:87–93.PubMedCrossRef
32.
go back to reference Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol. 2011;18:1125–32.PubMedPubMedCentralCrossRef Kuo J, Nardelli DT, Warner TF, Callister SM, Schell RF. Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice. Clin Vaccine Immunol. 2011;18:1125–32.PubMedPubMedCentralCrossRef
33.
go back to reference Teng DK, Liu Y, Lv YF, Wang L, Zhang W, Wang JP, Li Y. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol. 2019;70:252–9.PubMedCrossRef Teng DK, Liu Y, Lv YF, Wang L, Zhang W, Wang JP, Li Y. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol. 2019;70:252–9.PubMedCrossRef
34.
go back to reference Pan X, Xu K, Li Y, Wang X, Peng X, Li M, Li Y. Interleukin-35 expression protects against cigarette smoke-induced lung inflammation in mice. Biomed Pharmacother. 2019;110:727–32.PubMedCrossRef Pan X, Xu K, Li Y, Wang X, Peng X, Li M, Li Y. Interleukin-35 expression protects against cigarette smoke-induced lung inflammation in mice. Biomed Pharmacother. 2019;110:727–32.PubMedCrossRef
35.
go back to reference Dong J, Wong CK, Cai Z, Jiao D, Chu M, Lam CW. Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells. Allergy. 2015;70:921–32.PubMedCrossRef Dong J, Wong CK, Cai Z, Jiao D, Chu M, Lam CW. Amelioration of allergic airway inflammation in mice by regulatory IL-35 through dampening inflammatory dendritic cells. Allergy. 2015;70:921–32.PubMedCrossRef
36.
go back to reference Yu W, Ge M, Lu S, Shi J, Li X, Zhang J, Wang M, Huang J, Shao Y, Huang Z, et al. Anti-inflammatory effects of interleukin-35 in acquired aplastic anemia. Cytokine. 2015;76:409–16.PubMedCrossRef Yu W, Ge M, Lu S, Shi J, Li X, Zhang J, Wang M, Huang J, Shao Y, Huang Z, et al. Anti-inflammatory effects of interleukin-35 in acquired aplastic anemia. Cytokine. 2015;76:409–16.PubMedCrossRef
37.
go back to reference Huang Y, Lin YZ, Shi Y, Ji QW. IL-35: a potential target for the treatment of atherosclerosis. Pharmazie. 2013;68:793–5.PubMed Huang Y, Lin YZ, Shi Y, Ji QW. IL-35: a potential target for the treatment of atherosclerosis. Pharmazie. 2013;68:793–5.PubMed
38.
go back to reference Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37:3021–9.PubMedCrossRef Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37:3021–9.PubMedCrossRef
39.
go back to reference Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141:1875–86.PubMedCrossRef Wirtz S, Billmeier U, McHedlidze T, Blumberg RS, Neurath MF. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology. 2011;141:1875–86.PubMedCrossRef
40.
go back to reference Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184:7144–53.PubMedCrossRef Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184:7144–53.PubMedCrossRef
41.
go back to reference Li Y, Pan X, Peng X, Li S, Zhou Y, Zheng X, Li M. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma. Inflamm Res. 2015;64:767–74.PubMedCrossRef Li Y, Pan X, Peng X, Li S, Zhou Y, Zheng X, Li M. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma. Inflamm Res. 2015;64:767–74.PubMedCrossRef
42.
go back to reference Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN: IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease.J Allergy Clin Immunol2012, 129:207–215 e201–205. Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN: IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease.J Allergy Clin Immunol2012, 129:207–215 e201–205.
43.
go back to reference Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37:3021–9..PubMedCrossRef Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37:3021–9..PubMedCrossRef
Metadata
Title
Different expression levels of interleukin-35 in asthma phenotypes
Authors
Wei Li
Ruihan Gao
Tong Xin
Peng Gao
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01356-6

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.